论文信息 - Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia. - 字舞流文

Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia.

M. Levis | A. Fathi | J. Altman | G. Schiller | R. Subach | Catherine C. Smith | G. Roboz | E. Wang | A. Perl | M. Kurman | K. Cheung | M. Johansen | M. Ando | G. Maier | T. Madden | Takeaki Suzuki